1 / 11

Hyperphosphatemia Market Report

The Hyperphosphatemia market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Hyperphosphatemia market size from 2018 to 2030. The report also covers current Hyperphosphatemia treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.<br><br>

yashb
Download Presentation

Hyperphosphatemia Market Report

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Hyperphosphatemia Presented by- DelveInsight Business Research

  2. What is Hyperphosphatemia? Hyperphosphatemia is a condition characterized by an increase in serum phosphate level above 4.5 mg/100 mL. The condition usually occurs due to a decrement in renal function, commonly among chronic kidney disease (CKD) patients, in which phosphate levels shoot up abnormally high. The condition may result from varying factors like an increase in phosphate intake, a decrease in phosphate excretion, or a disorder that shifts intracellular phosphate to extracellular space; the health of kidneys plays a crucial role as it is the kidneys that control the amount of phosphate in the blood. Moreover, phosphate absorption can also be increased with Vitamin D, leading to Hyperphosphatemia through increased gut absorption of phosphate

  3. What is Hyperphosphatemia Diagnosis? The condition is diagnosed by serum phosphate measurement with specific blood tests, which measure the levels of phosphate, calcium, magnesium, blood urea nitrogen, creatinine, vitamin D and parathyroid hormone. It is important to diagnose and find the underlying cause of hyperphosphatemia to treat and restore normal phosphate metabolism. Original Source:- Hyperphosphatemia Market Size

  4. What is Hyperphosphatemia Market Insights and Treatment? Treatment for hyperphosphatemia depends on the underlying condition. For people with kidney disease, a combination of diet and medication is used to keep phosphate levels under control. In patients with persistently or progressively elevated phosphate despite dietary phosphate restriction, phosphate binders are the agent of choice. These are also used concurrently with dietary restriction when phosphate levels at presentation are very high (greater than 6 mg/dl). Phosphate binders reduce the absorption of dietary phosphate in the gastrointestinal tract by exchanging the anion phosphate with an active cation (carbonate, acetate, oxyhydroxide, and citrate) to form a nonabsorbable compound that gets excreted in the feces.

  5. How Many Regions Are Covered? The US EU5 (Germany, France, Italy, Spain, and the United Kingdom) Japan

  6. What are the Hyperphosphatemia Market Share and Drug Chapters? The drug chapter segment of the Hyperphosphatemia report encloses the detailed analysis of Hyperphosphatemia mid and late-stage pipeline drugs. It also helps to understand the Hyperphosphatemia clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details of each included drug, and the latest news and press releases.

  7. What is the Hyperphosphatemia Report Scope? • The report covers the descriptive overview of Hyperphosphatemia, explaining its causes, signs and symptoms, pathogenesis and currently available therapies. • Comprehensive insight has been provided into the Hyperphosphatemia epidemiology and treatment. • Additionally, an all-inclusive account of both the current and emerging therapies for Hyperphosphatemia are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape. • A detailed review of the Hyperphosphatemia market; historical and forecasted is included in the report, covering the 7MM, China and Taiwan drug outreach. • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM, China and Taiwan Hyperphosphatemia market.

  8. What are the Hyperphosphatemia Report Highlights? • In the coming years, the Hyperphosphatemia market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market. • The companies and academics are working to assess challenges and seek opportunities that could influence Hyperphosphatemia R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition. • Positive results by major key players Ardelyx and Shield Therapeutics may increase market size in the coming years, assisted by an increase in the Hyperphosphatemia incident population pool.

  9. info@delveinsight.com ybhardwaj@delveinsight.com +91-9650213330 Do You Have Any Question or Query? Please keep this slide for attribution

  10. Thank You

More Related